Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:BCAX NYSE:CYBN NASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$5.17-8.8%$4.26$2.12▼$6.00$565.43M1.823.06 million shs4.55 million shsBCAXBicara Therapeutics$10.75+3.0%$11.38$7.80▼$28.09$569.64MN/A309,701 shs263,145 shsCYBNCybin$6.05+0.8%$7.10$4.81▼$13.88$142.72M0.68354,950 shs444,866 shsOLMAOlema Pharmaceuticals$8.35+2.2%$5.87$2.86▼$13.93$560.74M1.921.17 million shs1.12 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-8.82%+0.58%+29.90%+61.06%+1.57%BCAXBicara Therapeutics+2.97%-5.54%-9.21%+13.04%-58.02%CYBNCybin+0.83%+0.67%-15.38%-22.83%+1,539.57%OLMAOlema Pharmaceuticals+2.19%+4.36%+44.95%+78.02%-38.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$5.17-8.8%$4.26$2.12▼$6.00$565.43M1.823.06 million shs4.55 million shsBCAXBicara Therapeutics$10.75+3.0%$11.38$7.80▼$28.09$569.64MN/A309,701 shs263,145 shsCYBNCybin$6.05+0.8%$7.10$4.81▼$13.88$142.72M0.68354,950 shs444,866 shsOLMAOlema Pharmaceuticals$8.35+2.2%$5.87$2.86▼$13.93$560.74M1.921.17 million shs1.12 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-8.82%+0.58%+29.90%+61.06%+1.57%BCAXBicara Therapeutics+2.97%-5.54%-9.21%+13.04%-58.02%CYBNCybin+0.83%+0.67%-15.38%-22.83%+1,539.57%OLMAOlema Pharmaceuticals+2.19%+4.36%+44.95%+78.02%-38.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$10.2998.95% UpsideBCAXBicara Therapeutics 3.00Buy$32.25200.01% UpsideCYBNCybin 3.25Buy$85.001,304.96% UpsideOLMAOlema Pharmaceuticals 2.83Moderate Buy$24.00187.46% UpsideCurrent Analyst Ratings BreakdownLatest CYBN, BCAX, AQST, and OLMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/8/2025AQSTAquestive TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.009/3/2025AQSTAquestive TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.008/22/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$41.00 ➝ $40.008/18/2025BCAXBicara TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.008/14/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$28.00 ➝ $29.008/13/2025AQSTAquestive TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/12/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$30.008/12/2025OLMAOlema PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $21.008/11/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$57.56M8.96N/AN/A($0.66) per share-7.83BCAXBicara TherapeuticsN/AN/AN/AN/A$9.04 per shareN/ACYBNCybinN/AN/AN/AN/A$10.83 per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$44.14M-$0.70N/AN/AN/A-147.38%N/A-63.87%11/3/2025 (Estimated)BCAXBicara Therapeutics-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)CYBNCybin-$57.88M-$4.60N/AN/AN/AN/A-37.58%-36.59%N/AOLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)Latest CYBN, BCAX, AQST, and OLMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54-$0.50+$0.04-$0.50N/AN/A8/11/2025Q2 2025AQSTAquestive Therapeutics-$0.18-$0.14+$0.04-$0.14$11.32 million$10.00 million8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/ABCAXBicara TherapeuticsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A3.533.18BCAXBicara TherapeuticsN/A25.8025.80CYBNCybinN/A24.2424.24OLMAOlema Pharmaceuticals0.0111.0911.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%BCAXBicara TherapeuticsN/ACYBNCybin17.94%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics7.85%BCAXBicara TherapeuticsN/ACYBNCybin15.00%OLMAOlema Pharmaceuticals16.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16099.72 million91.90 millionOptionableBCAXBicara Therapeutics3254.56 millionN/AN/ACYBNCybin5023.59 million17.96 millionNot OptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionableCYBN, BCAX, AQST, and OLMA HeadlinesRecent News About These CompaniesGoldman Sachs Group Inc. Raises Stock Position in Olema Pharmaceuticals, Inc. $OLMASeptember 20 at 3:24 AM | marketbeat.comCyrus Harmon Sells 10,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) StockSeptember 19, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 10,000 SharesSeptember 19, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 10.2% - Here's What HappenedSeptember 19, 2025 | marketbeat.comWoodline Partners LP Boosts Holdings in Olema Pharmaceuticals, Inc. $OLMASeptember 15, 2025 | marketbeat.comCubist Systematic Strategies LLC Buys 67,682 Shares of Olema Pharmaceuticals, Inc. $OLMASeptember 14, 2025 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $24.00 Consensus Price Target from BrokeragesSeptember 14, 2025 | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Rating Upgraded by Zacks ResearchSeptember 13, 2025 | marketbeat.comOLMA Stock Soars 47% in September So Far on Second PFE DealSeptember 12, 2025 | zacks.comOlema Pharmaceuticals (NASDAQ:OLMA) Upgraded at Zacks ResearchSeptember 12, 2025 | americanbankingnews.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 11, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Down 7.2% - Should You Sell?September 10, 2025 | marketbeat.comInvesco Ltd. Purchases 34,362 Shares of Olema Pharmaceuticals, Inc. $OLMASeptember 10, 2025 | marketbeat.comPDT Partners LLC Makes New Investment in Olema Pharmaceuticals, Inc. $OLMASeptember 8, 2025 | marketbeat.comHC Wainwright Issues Positive Outlook for OLMA EarningsSeptember 7, 2025 | marketbeat.comOppenheimer Reaffirms "Outperform" Rating for Olema Pharmaceuticals (NASDAQ:OLMA)September 5, 2025 | marketbeat.comBVF Inc. IL Sells 420,000 Shares of Olema Pharmaceuticals, Inc. $OLMASeptember 5, 2025 | marketbeat.comOlema Pharmaceuticals, Inc. $OLMA is Bain Capital Life Sciences Investors LLC's 8th Largest PositionSeptember 5, 2025 | marketbeat.comPfizer collaboration with Olema may spark future bidding war - analystSeptember 3, 2025 | msn.comOlema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement PlanSeptember 3, 2025 | quiverquant.comQOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYBN, BCAX, AQST, and OLMA Company DescriptionsAquestive Therapeutics NASDAQ:AQST$5.17 -0.50 (-8.82%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$5.24 +0.08 (+1.45%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Bicara Therapeutics NASDAQ:BCAX$10.75 +0.31 (+2.97%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$10.82 +0.07 (+0.70%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Cybin NYSE:CYBN$6.05 +0.05 (+0.83%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$6.23 +0.18 (+2.98%) As of 08:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Olema Pharmaceuticals NASDAQ:OLMA$8.35 +0.18 (+2.19%) Closing price 09/22/2025 03:58 PM EasternExtended Trading$8.35 +0.00 (+0.01%) As of 08:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Why Robinhood Stock Is Soaring—and What Comes Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
